A prospective clinical trial comparing OL-HDF with HF-HD showed a significant decrease in pretreatment serum concentrations of complement factor D in OL-HDF-treated patients, emphasizing treatment modality-related alleviation of complement-inflammation factors (78). The gene discussed is CFD; the disease is hydrops fetalis.